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Abstract 
Autosomal dominant mutations in LITAF are responsible for the rare demyelinating peripheral neuropathy, Charcot–
Marie–Tooth disease type 1C (CMT1C). The LITAF protein is expressed in many human cell types and we have investi-
gated the consequences of two different LITAF mutations in primary fibroblasts from CMT1C patients using confocal 
and electron microscopy. We observed the appearance of vacuolation/enlargement of late endocytic compartments 
(late endosomes and lysosomes). This vacuolation was also observed after knocking out LITAF from either control 
human fibroblasts or from the CMT1C patient-derived cells, consistent with it being the result of loss-of-function 
mutations in the CMT1C fibroblasts. The vacuolation was similar to that previously observed in fibroblasts from CMT4J 
patients, which have autosomal recessive mutations in FIG4. The FIG4 protein is a component of a phosphoinositide 
kinase complex that synthesises phosphatidylinositol 3,5-bisphosphate on the limiting membrane of late endosomes. 
Phosphatidylinositol 3,5-bisphosphate activates the release of lysosomal  Ca2+ through the cation channel TRPML1, 
which is required to maintain the homeostasis of endosomes and lysosomes in mammalian cells. We observed that a 
small molecule activator of TRPML1, ML-SA1, was able to rescue the vacuolation phenotype of LITAF knockout, FIG4 
knockout and CMT1C patient fibroblasts. Our data describe the first cellular phenotype common to two different sub-
types of demyelinating CMT and are consistent with LITAF and FIG4 functioning on a common endolysosomal path-
way that is required to maintain the homeostasis of late endosomes and lysosomes. Although our experiments were 
on human fibroblasts, they have implications for our understanding of the molecular pathogenesis and approaches 
to therapy in two subtypes of demyelinating Charcot–Marie–Tooth disease.
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Introduction
The Charcot–Marie–Tooth diseases (CMT) encompass 
a large group of progressive inherited peripheral neu-
ropathies leading to muscle atrophy, weakness and sen-
sory impairment of the limbs. Thanks to advances in 
DNA sequencing, more than 100 genes are now known 
to be associated with CMT [19, 34, 41]. Subtypes of CMT 
have long been classified into ‘axonal’ and ‘demyelinat-
ing’ subgroups using neurophysiological criteria. This 
distinction has proved helpful by reflecting the presumed 
primary sites of underlying cellular dysfunction as the 
axons of peripheral nerves or the supporting Schwann 
cells, respectively. Schwann cells, derived from the neu-
ral crest, engulf peripheral nerve axons during develop-
ment and, when triggered to do so via the stimuation of 
surface receptors by specific growth factors, wrap layers 
of plasma membrane around larger axons to form mye-
lin. This in turn leads to the clustering of ion channels in 
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highly specialised regions called nodes of Ranvier, facili-
tating the efficient propagation of action potentials along 
axons from the spinal cord to the peripheries and vice 
versa. ‘Demyelinating’ subtypes of CMT are therefore 
characterised by the defective formation or maintenance 
of the myelinated state by the Schwann cell, eventually 
leading to axonal degeneration and clinical manifestation 
[3].
Of the genes known to be associated with demyeli-
nating CMT, three main functional categories emerge: 
genes encoding proteins that play a structural role in the 
formation and maintenance of the myelin sheath; genes 
encoding transcription factors that are crucial in acti-
vating the Schwann cell’s myelination programme when 
appropriately stimulated; and, finally, genes encoding 
proteins known or predicted to function in intracellular 
membrane traffic. In the latter group, most of these pro-
teins are widely expressed across different tissues and cell 
types, and several are known to function specifically in 
the endolysosomal pathway [5]. This suggests the exist-
ence of pathogenic mechanisms—and hence potential 
therapeutic targets – that are common to more than one 
subtype of CMT. For example, mutations in FIG4 and 
MTMR2/13 are associated with the autosomal recessive 
subtypes of demyelinating CMT known as CMT4J [6, 30, 
44] and CMT4B [17], respectively. These genes encode 
proteins involved in endolysosomal function; FIG4 is a 
lipid phosphatase which, in conjunction with the scaf-
folding protein, VAC14, and the lipid kinase, PIKfyve, 
forms part of the PIKfyve protein complex responsi-
ble for generating PtdIns(3,5)P2 (phosphatidylinositol 
3,5-bisphosphate) from PtdIns(3)P (phosphatidylinositol 
3-phosphate) at the limiting membrane of endosomes [9, 
18]. In turn, PtdIns(3,5)P2 regulates the homeostasis of 
endosomes and lysosomes in mammalian cells by mecha-
nisms including the activation of the lysosomal cation 
channel TRPML1 (transient receptor potential mucolipin 
1) [2], resulting in the release of localised Ca2 + stores 
[8]. In contrast, MTMR2/13 exerts an effect on endolys-
osomes by dephosphorylating both PtdIns(3)P and 
PtdIns(3,5)P2 leading to a proposed functional link with 
FIG4 [17, 42].
CMT1C is an autosomal dominant form of demyelinat-
ing CMT associated with mutations in LITAF (Lipopol-
ysacharide-induced tumour necrosis factor-α factor). 
LITAF, also known as SIMPLE (Small integral mem-
brane protein of the lysosome/late endosome), encodes a 
widely-expressed 17 kDa monotopic integral membrane 
protein composed of an N-terminal proline-rich region 
and an evolutionary conserved zinc-binding C-terminal 
‘LITAF domain’ that anchors the protein to endosomal 
membranes [14, 32]. Furthermore, a cargo sorting role 
in endocytic membrane trafficking is supported by the 
ability of the proline-rich region of LITAF to interact 
with the ESCRT protein, TSG101 [20, 37], as well as the 
ITCH/NEDD4 family of E3-ubiquitin ligases [10, 37]. We 
and others have shown that both the N- and C-termini 
of LITAF are present on the cytosolic face of endosomes 
and that membrane association is mediated by the C-ter-
minal LITAF domain via a predicted hydrophobic helix 
and specific interactions with phosphoethanolamine 
(PE) head groups [14, 32]. Interestingly, all CMT1C-
associated pathogenic mutations are found in and around 
this hydrophobic region within the C-terminal LITAF 
domain and have been proposed to disrupt membrane 
interaction and lead to protein instability [14, 21].
Despite our expanding knowledge concerning the 
genes associated with CMT, no reversible treatments 
currently exist. The development of targeted effective 
treatments for CMT will therefore rely on improving our 
understanding of the underlying cellular pathomecha-
nisms for each subtype. Moreover, some individual sub-
types of CMT linked to single genes might in fact require 
different treatment approaches depending on the specific 
mutation, thereby adding an additional level of com-
plexity to drug development. While therapeutic strate-
gies aimed at introducing functional wild type copies of 
CMT-asscociated genes encoding proteins involved in 
membrane trafficking into Schwann cells have shown 
real promise in autosomal recessive forms of the disease 
using viral delivery systems [35], the optimal therapeutic 
approach towards autosomal dominant subtypes such 
as CMT1C remains unclear. A key question that needs 
answering before treatments for CMT1C can be devel-
oped is whether the expression of a single copy of the 
LITAF gene harbouring disease-associated mutations 
causes a toxic ‘gain of function’, or whether the heterozy-
gous presence of the mutated protein leads to loss of 
function in either a ‘haploinsufficent’ or ‘dominant-neg-
ative’ fashion, mimicking any phenotype that might be 
the result of the absence of wild-type protein expression 
in vivo.
Given the localisation of LITAF to endosomes and the 
prediction that disease-causing mutations disrupt the 
interaction with membranes and lead to protein instabil-
ity [14, 21], we set out to determine the consequences of 
these mutations on the morphology of endosomal and 
lysosomal compartments in primary fibroblasts from two 
CMT1C patients harbouring different pathogenic LITAF 
mutations. Having established the cellular phenotype, we 
then compared the observed morphology with that of the 
same compartments in fibroblasts depleted of LITAF or 
the CMT4J-associated protein, FIG4. Finally, we inves-
tigated the rescue of these observed phenotypes with a 
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small molecule activator of TRPML1, previously shown 
to rescue the phenotype associated with mutations in 
FIG4 [46], allowing us to propose a potential therapeutic 
target common to more than one subtype of CMT.
Materials and methods
Antibodies
Antibodies used for immunofluorescence were as fol-
lows; anti-LAMP1; mouse monoclonal, H4A3 from 
Santa-Cruz, anti-Cathepsin D; rabbit polyclonal, 219361 
from Calbiochem, anti-APPL1; rabbit polyclonal, H-96 
from Santa Cruz, anti-EEA1; mouse monoclonal, 610457 
from BD Transduction, anti-CD63; mouse monoclonal, 
IB5, a gift from Prof. Mark Marsh (University College 
London), anti-LBPA; mouse monoclonal, 6C4, a gift from 
Prof. Jean Gruenberg (University of Geneva), anti-ubiq-
uitin; mouse monoclonal, FK2 from Enzo Life Sciences, 
anti-LC3B; rabbit polyclonal, 2775S from Cell Signalling 
Technology, anti-CIMPR; mouse monoclonal, ab2733 
(2G11) from Abcam, anti-TGN46; sheep polyclonal, 
AHP500 from Bio-Rad, anti-LITAF; mouse monoclonal, 
611614 from BD Biosciences.
Antibodies used only for Western blotting were anti-
FIG4; rabbit polyclonal, ab221758 from Abcam, anti-
alpha-Tubulin; mouse monoclonal, T9026 from Sigma.
Fibroblast generation
Human skin fibroblasts were collected by biopsy from 2 
patients with CMT1C via the Centre for Neuromuscular 
Diseases, UCL and at Newcastle University. Fibroblasts 
were supplied by the MRC Centre for Neuromuscular 
Disease Biobank London (REC reference number 06/
Q0406/33) for one patient. An age matched control to 
the fibroblasts harbouring mutations (ages 39 and 46) 
was also collected. All fibroblast cultures were grown in 
high-glucose DMEM supplemented with 10% FBS, 2 mM 
Glutamax and 50 U/ml penicillin and 50 µg/ml strepto-
mycin. Patients gave consent to the studies “Genotype 
and phenotype in inherited neurological diseases” study 
(REC: 13/YH/0310, IRAS ID: 2042290) and CMT: A Nat-
ural History Study (IRAS ID 30165; REC: 09/H0716/61).
Lentivirus generation and transduction
Mixed knockout fibroblasts were generated using a len-
tiviral CRISPR/Cas9 method. Lentiviral vectors (see 
below) were cotransfected into HEK293ET cells with 
pCMVR8.91 (“199”) and pMD.G (VSV-G) (“200”) pack-
aging plasmids using TransIT-293 (Mirus Bio, USA). 
Viral supernatants were collected 48 h after transfection, 
passed through 0.45 μm filters and fibroblasts transduced 
by ‘spinfection’—viral supernatants were centrifuged at 
1800  rpm in a benchtop centrifugue at 37  °C for 3  h to 
enhance viral transduction.
Fibroblasts were first transduced with Cas9-encoding 
lentivirus generated using pHRSIN-SFFV-Cas9-PGK-
Hygro. 48  h after transduction, cells were selected with 
200  µg/ml hygromycin for 9  days. GuideRNAs were 
cloned into the lentiviral pKLV-U6gRNA-EF-(BbsI)-
PGK-Puro2A-BFP vector, and 48  h after transduction 
cells were selected with 1 µg/ml puromycin for 5 days.
Guide RNA sequences; LITAF (5′ CAC CGA CAA CAC 
ATT TGG ATA GGG 3′), FIG4 (5′ CAC CGG AGT TTT 
CCA TCC CACTG 3′).
Polyclonal fibroblasts were generated and assayed for 
expression of the LITAF/FIG4 protein by immunofluo-
rescence and Western blotting.
Immunofluorescence
Cells were grown on glass coverslips and fixed using 4% 
PFA/PBS. Cells were quenched with 15  mM glycine/
PBS and permeabilised with 0.1% saponin/PBS. Block-
ing and subsequent steps were performed with 1% BSA, 
0.01% saponin in PBS. Cells were mounted on slides 
with mounting medium containing DAPI (Invitrogen). 
Cells were imaged using a LSM780 confocal microscope 
(63×/1.4 NA oil immersion objective; ZEISS).
Conventional electron microscopy
Unless stated otherwise, cells were fixed with 2% PFA, 
2.5% glutaraldehyde, 0.1 M cacodylate buffer, pH 7.2 before 
being scraped and pelleted. Pellets were secondarily fixed 
with 1% osmium tetroxide/1.5% potassium ferrocyanide 
and then incubated with 1% tannic acid in 0.1  M caco-
dylate buffer to enhance membrane contrast. Cells were 
dehydrated using increasing percentages of ethanol before 
resin was infiltrated using a 1:1 mix of propylene oxide and 
CY212 Epoxy resin. Samples were then transferred into 
neat CY212 Epoxy resin before being embedded in beam 
capsules. Resin was cured overnight at 65  °C. Ultrathin 
sections were cut using a diamond knife mounted to a 
Reichart ultracut S ultramicrotome. Sections were col-
lected onto piloform-coated slot grids and stained using 
lead citrate. Sections were viewed on a FEI Tecnai trans-
mission electron microscope at a working voltage of 80 kV.
Cryo‑immunogold electron microscopy
Cells were fixed with 4% PFA/0.1% glutaraldehyde/0.25 M 
HEPES buffer pH7.4, scraped and pelleted. Pellets were 
supported in 10% gelatine before being infused with 
sucrose/PVP. 70 nm sections were cut at − 120  °C using 
a Diatome diamond knife mounted to a Leica UC7 cryo 
ultramicrotome. The sections were picked up with either 
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2.3 M sucrose, or a mixture of methylcellulose and sucrose 
and placed onto formvar and carbon-coated gold grids.
Thawed sections were subsequently labelled using 
antibodies followed by protein-A gold as previously 
described [39]. Murine monoclonal antibodies were fol-
lowed by bridging using rabbit anti-mouse antibodies, 
before being labelled with protein-A gold. Sections were 
visualised on a FEI Tecnai transmission electron micro-
scope at a working voltage of 80 kV.
BSA‑gold uptake
BSA-gold was prepared as previously described [38]. 
Cells were grown on Thermanox coverslips and incu-
bated with BSA-gold continuously for 2  h before being 
washed with PBS, fixed and prepared for conventional 
EM as above.
HRP‑DAB chemistry
Cells were grown on Thermanox coverslips and incubated 
with 5 mg/ml HRP in culture media for 4 h, before being 
washed four times with PBS and chased in full media 
overnight. Cells were then fixed with 2% PFA, 2.5% glu-
taraldehyde, 0.1 M cacodylate buffer before being washed 
with 15 mM glycine. Subsequently, cells were incubated 
with 1.5  mg/ml DAB (3, 3,’-Diaminobenzidine), in TBS 
(pH 7.6) containing 0.05%  H2O2 at 4  °C, in the dark for 
30 min. Cells were washed with 0.1 M cacodylate buffer 
before being post-fixed with 1% osmium:1.5% potassium 
ferrocyanide, and subsequently processed as described 
above.
Correlative Light and Electron Microscopy (CLEM)
Fibroblasts were plated to gridded coverslips with alpha-
numeric coordinates (P35G-1.5-14-CGRD, MatTek) and 
left to settle before being transfected with 2 μg PX-GFP 
plasmid using Xtreme Gene HP (Roche). Two days fol-
lowing transfection, cells were fixed with 2% PFA, 2.5% 
glutaraldehyde, 0.1 M cacodylate buffer. Cells were then 
stained with Hoechst (to stain the nucleus) for 2  min, 
before being washed with 0.1  M cacodylate buffer. PX-
GFP fluorescence was imaged on an LSM780 confocal 
microscope (63×/1.4 NA oil immersion objective; ZEISS) 
and the coordinates of cells selected for imaging were 
recorded. To prepare for electron microscopy, cells were 
secondarily fixed with 1% osmium tetroxide/1.5% potas-
sium ferrocyanide and then incubated with 1% tannic 
acid in 0.1  M cacodylate buffer to enhance membrane 
contrast. Samples were then processed as previously 
described until embedding, where pre-baked epoxy stubs 
were inverted over areas of interest. After baking, the 
dish was removed using liquid nitrogen. Areas of inter-
est were identified by alpha-numeric coordinates and 
70 nm ultrathin sections were collected using a Diatome 
diamond knife attached to an ultracut UCT ultrami-
crotome (Leica). Sections were stained with lead citrate 
before being imaged on a Tecnai Spirit transmission elec-
tron microscope (FEI) at an operating voltage of 80 kV.
Western blots
Fibroblasts were rinsed once in PBS and lysed in RIPA 
buffer containing 50 mM Tris, pH 7.4, 150 mM sodium 
chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 1 mM EDTA, complete protease inhibitor (Roche). 
Lysates were centrifuged at 20,000×g at 4  °C for 20 min 
and the supernatant was retained. The protein concen-
tration of the lysed sample was determined using Preci-
sion Red reagent (Cytoskeleton, Inc.). Equal amounts of 
protein were mixed with NuPAGE® LDS Sample Buffer 
(Thermo Scientific) and were heated at 70 °C for 10 min. 
Samples were separated by SDS–PAGE, followed by 
semi-dry transfer onto a PVDF membrane (Whatman). 
Membranes were blocked with 5% (w/v) dried milk in 
PBS prior to incubation with primary antibody. The 
membrane was washed with PBST (PBS, 0.3% Tween) 
first for 15 min, then twice for five minutes before incu-
bation with Horseradish Peroxidase (HRP)-Conjugated 
secondary antibody. Western blots were developed 
using Pierce ECL Western Blotting Substrate (Thermo 
scientific).
ML‑SA1
The synthetic TRPML1 activator, ML-SA1 (Tocris Biosci-
ence) was dissolved in DMSO at a stock concentration 
of 20 mM. ML-SA1 was used at a final concentration of 
40 µM in full media for 36 h as previously described [46].
Lysosome quantification
To determine the proportion of cells with enlarged late 
endosomes/lysosomes, fixed cells were permeabilised, 
labelled with LAMP1 and processed for immunofluo-
rescence microscopy as previously described. At least 23 
cells were recorded per cell line, per independent experi-
mental conditions. Cells were imaged at random, and the 
largest LAMP1-positive organelle per cell was measured 
using ZEN Black (Zeiss). Three-independent experiments 
were performed, allowing means and standard error of 
means calculated.
Unpaired, two-tailed T tests were performed. p < 0.05 *, 
p < 0.01 **, p > 0.001 ***.
Results
We obtained fibroblasts from the skin of two CMT1C 
patients with known mutations in LITAF (L125P; 
p.Leu125Pro and T115N; p.Thr115Asn), and age- and 
sex-matched controls. The clinical features of the patients 
are summarised in Table  1. Both mutations are within 
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the hydrophobic region of the LITAF domain and are 
predicted to disrupt its helical propensity and interac-
tion with endosomal membranes [14] (Fig.  1a). LITAF 
domains are conserved in eukaryotes and target proteins 
to membranes, but do not traverse the lipid bilayer, rather 
becoming anchored to the membrane via an in-plane 
helical membrane anchor [14] (Fig.  1b). To determine 
whether the mutations in LITAF altered the number or 
position of late endosomes/lysosomes, we performed 
confocal immunofluorescence microscopy and observed 
that these organelles were enlarged in both patients’ 
fibroblasts, by staining with the late endosome/lysosome 
markers LAMP1 (lysosomal-associate membrane pro-
tein 1) and Cathepsin D (Fig. 1c). LAMP1 could routinely 
be observed as rings, rather than puncta in both L125P 
and T115N fibroblasts, and Cathepsin D staining often 
appeared to be lost from, or moved to the edge of, these 
enlarged structures. Interestingly, no other endomem-
brane-related organelle markers that we tested displayed 
consistent differences in staining patterns (Additional 
file 1: Fig. 1). There was no alteration in the staining pat-
terns of the early endosome markers APPL1 (adaptor 
protein, phosphotyrosine interacting with PH domain 
and leucine zipper 1) and EEA1 (early endosome antigen 
1), the trans-Golgi network marker TGN46 or the ciMPR 
(the cation independent mannose 6-phosphate recep-
tor), which shuttles between the TGN and endosomes to 
deliver newly synthesised lysosomal hydrolases. Despite 
the alterations in LAMP1 and Cathepsin D staining, there 
was no obvious change in staining the late endosome/
lysosome markers CD63 and LBPA (lysosbisphosphatidic 
acid), but these are both found mainly on intraluminal 
membranes in contrast to LAMP1 which labels mainly 
the limiting membrane of late endosomes and lysosomes 
[13, 43]. The lack of any increase in ubiquitin staining or 
of LC3 staining in the patients’ fibroblasts is consistent 
with no significant alteration in autophagy. By western 
blotting, we examined the levels of LITAF in the patients’ 
cells. No change in the level of LITAF was observed in 
the T115N patient fibroblasts compared to controls, but 
there was some reduction in the L125P cells, implying 
that this mutation may result in increased instability of 
the protein (Fig. 1d, Additional file 2: Fig. 2). Neverthe-
less there were easily detectable concentrations of LITAF 
in the fibroblasts from both patients.
To investigate the phenotype of enlarged late 
endosomes and lysosomes further, we performed conven-
tional transmission electron microscopy (EM) on control 
and patient-derived fibroblasts. The fibroblasts from both 
patients contained abnormal, large, vacuolated compart-
ments, with the membranes of these swollen compart-
ments often appearing to be interconnected (Fig.  1e). 
To clarify further the endocytic nature of these vacu-
olated compartments, we incubated T115N cells with 
endocytic tracers that are taken up by fluid phase endo-
cytosis and can be visualised by EM. Both endocytosed 
BSA-gold and the electron dense product of horserad-
ish peroxidase (HRP) catalysis were found within vacu-
olated organelles (Fig. 2a, b). BSA-gold was observed to 
be flocculated, indicating that the BSA had been hydro-
lysed [4]. The resultant gold particles were preferentially 
localised to the dense cores of the vacuolated organelles, 
highlighted by arrowheads (Fig.  2a). Cryo-immunogold 
EM of T115N fibroblasts confirmed that the vacuolated 
compartments were positive for the late endosome/
lysosome markers—LAMP1 was localised to be limiting 
membrane and Cathepsin D to the dense cores within the 
lumen of the vacuolated structures (Fig.  2c, Additional 
file 3: Fig. 3). To assess the localisation of PtdIns(3)P, we 
performed CLEM (correlative light and electron micros-
copy) on T115N patient fibroblasts transfected with the 
PtdIns(3)P reporter PX-GFP. By fluorescence microscopy, 
the PX-GFP was found in small puncta consistent with its 
expected endosomal localisation, but also in larger com-
partments, which correlated with enlarged, vacuolated 
structures as seen by electron microscopy (Fig. 3).
Table 1 Clinical features
Weakness: − normal, +  ≥ 4 in distal muscles, ++ < 4 in distal muscles, +++ 
proximal weakness (knee flexion and extension, elbow flexion and extension, 
and/or above); Pinprick and vibration sense: − normal, + reduced below wrist/
ankle, ++ reduced below elbow/knee, +++ reduced at or above elbow/knee
N  normal, ND not done, VEP visual evoked potentials, BAEP  brain stem auditory 
evoked potentials, CMCT  central motor conduction time, CMTES  Charcot–
Marie–Tooth evaluation score (max score 28/28), CMTNS  Charcot–Marie–Tooth 
Neuropathy Score (max score 36/36)
Patient 1 2
Mutations c.374 T > C; p.Leu125Pro c.334G > A
p.Thr115Asn
Sex/age M/39 F/46
Age of onset First decade 30 years
Presenting symptom High arches, Foot deformity (asym-
metric), pain on 
longer walks
Weakness
 Upper limbs − −
 Lower limbs + +
Pinprick
 Upper limbs − −
 Lower limbs ++ ++
Vibration
 Upper limbs − −
 Lower limbs + +
Skeletal deformities Severe pes cavus Pes cavus, hammer toes
CMTES 6 7
CMTNS ND 9
Aid for walking No No
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To determine whether mutations in LITAF were induc-
ing the observed phenotypes, or whether mutations were 
inhibiting the function of LITAF (toxic gain-of-function 
versus overall loss-of-function), we generated LITAF 
KO (knock out) cells from control as well as T115N and 
L125P patient fibroblasts using CRISPR/Cas9. Cells were 
transduced with Cas9 and selected, before being trans-
duced with gRNA against regions of LITAF conserved 
between WT and mutant LITAF and further selected. 
Mixed cell populations were generated and used for 
experiments because of the limited life spans of primary 
fibroblasts and our inability to grow single cell clonal lines 
to sufficient cell numbers. Western blotting confirmed 
the loss of LITAF expression in all three lines (Fig.  4a), 
and ~ 95% of cells were determined to be negative for 
any LITAF signal by confocal microscopy (Fig. 4b). Loss 
of LITAF from control fibroblasts induced phenotypes 
similar to those previously observed in T115N and L125P 
patient fibroblasts (Fig.  4c). Furthermore, the knockout 
of mutated LITAF from patient fibroblasts did not rescue 
Fig. 1 Patient-derived fibroblasts with mutations in LITAF display enlarged late endocytic compartments. a Schematic diagram to illustrate the 
domain organisation of the LITAF protein. The N terminus is characterised by a proline-rich region, followed by a ‘LITAF domain’ at the C terminus. 
Both T115N and L125P mutations are within the hydrophobic region of the LITAF domain (grey). b Diagram of the topology of the LITAF domain 
within the phospholipid bilayer (created with Adobe Photoshop). The predicted hydrophobic anchor (grey) of the LITAF domain, shown as a Rosetta 
structural model (from Ho et al. [14]), is embedded in the membrane’s phospholipid bilayer, but does not traverse it. c Representative confocal 
immunofluorescence images of control fibroblasts, and CMT1C patient-derived fibroblasts with mutations in LITAF (L125P, T115N) display enlarged 
late endocytic compartments, as shown by LAMP1 (green) and Cathepsin D (red) staining. Insets show LAMP1 staining in ‘rings’ as opposed to fine 
puncti in LITAF mutant cells. d Protein lysates were analysed by immunoblotting with an antibody raised against LITAF to confirm the expression 
of LITAF from control and CMT1C patient-derived fibroblasts. Alpha-tubulin served as loading control. Full-length blots are shown in Additional 
file 2: Fig. 2e) Conventional electron microscopy of control and LITAF patient-derived fibroblasts reveal abnormal, swollen, vacuolar compartments 
in LITAF mutant cells (L125P, T115N). Insets reveal vacuoles to be membrane bound; black arrows show interconnections, and white asterisks show 
dense core lysosomes
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Fig. 2 Characterisation of swollen compartments in LITAF mutant fibroblasts. a T115N patient-derived fibroblasts were incubated with the 
endocytic tracer BSA-gold for 16 h, and followed by a 4 h chase period to load lysosomes with BSA-gold. Conventional electron microscopy 
reveals the presence of flocculated BSA-gold within electron dense portions of vacuolated compartments (arrowheads). b Control or LITAF mutant 
fibroblasts were incubated with fluid-phase HRP for 4 h before being fixed. A DAB reaction was performed on cells before being processed for 
conventional electron microscopy (further examples in Additional file 3: Fig. 3). c Cryo immunogold electron microscopy was performed on T115N 
patient fibroblasts. Labelling with anti-LAMP1 antibody shows vacuolated compartments to be LAMP1 positive, and labelling with anti-Cathepsin D 
antibodies reveals labelling on electron dense patches within the lumen of such swollen compartments
Page 8 of 16Edgar et al. acta neuropathol commun           (2020) 8:165 
the observed EM phenotype, and swollen compartments 
persisted in these cells (data for LITAF KO in T115N 
patient cells shown in Fig. 4c). Taken together, these data 
support the hypothesis that expression of LITAF har-
bouring CMT1C-associated pathogenic mutations cause 
an overall loss of function phenotype, which in isolation 
could be explained either by haploinsufficiency or by a 
dominant negative mechanism, mimicking the results 
seen following depletion of the wild type protein.
As described above, FIG4 is a component of the PIK-
fyve complex and mutations in FIG4 cause CMT4J. 
Disease-causing mutations in FIG4, depletion of FIG4 
protein or inhibition of PIKfyve have all been reported 
to result in a morphological phenotype, with vacuolated 
late endosome and lysosome compartments [1, 2, 16, 
44] and similarities to the phenotype we observed in the 
CMT1C patients’ fibroblasts containing mutant LITAF. 
To investigate this similarity further, we used a CRISPR/
Cas9 protocol to generate FIG4 KO cells from control 
fibroblasts, the loss of protein in mixed cell populations 
being confirmed by western blotting (Fig.  5a). Using 
confocal immunofluorescence microscopy, we observed 
that FIG4 KO fibroblasts displayed enlarged, vacuolar 
LAMP1-positive compartments, often much larger than 
we had previously seen in the CMT1C patients’ cells 
(Fig. 5b). At the ultrastructural level, FIG4 KO fibroblasts 
displayed small vacuoles, as previously seen in CMT1C 
and LITAF KO fibroblasts, but additionally often dis-
played very large (over 10 μm) vacuoles (Fig. 5c). These 
vacuoles were largely devoid of any obvious luminal 
content and could also be seen with DIC (differential 
interference contrast) microscopy (Fig.  5d). As we had 
previously found the vacuoles observed in CMT1C cells 
to be PtdIns3P-rich, we wanted to determine whether 
the vacuoles generated following FIG4 KO were similarly 
rich in PtdIns(3)P, so we performed CLEM on FIG4 KO 
cells transiently expressing PX-GFP (Fig.  5d). Surpris-
ingly, only the smaller vacuoles and not the larger vacu-
oles appeared to be labelled with PX-GFP. This suggests 
that the very large vacuoles present following FIG4 KO 
represent additional disruption to the endolysosomal 
system, rather than an exaggerated form of disruption as 
observed following LITAF mutation or knock out. How-
ever, it is also feasible that the enlarged surface area of 
these very big vacuoles may dilute the signal from PX-
GFP to undetectable levels (Fig. 5d).
Fig. 3 Correlative Light and Electron Microscopy of T115N patient fibroblasts identifies vacuolated compartments to be PtdIns(3)P positive. CLEM 
of T115N patient fibroblast transfected with the PtdIns(3)P-probe, PX-GFP. Insets display the overlap between PX-GFP fluorescence and appearance 
of vacuolar structures by electron microscopy
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It has previously been shown that increased lyso-
some size observed in mouse FIG4 KO fibroblasts can 
be reduced by incubation with ML-SA1, a small mol-
ecule synthetic activator of the lysosomal cation chan-
nel TRPML1 [46]. This is consistent with FIG4′s normal 
function as part of the PIKfyve complex in synthesis-
ing PtdIns(3,5)P2, a natural activator of TRPML1. To 
see if ML-SA1 might also rescue the vacuolation phe-
notype in our human fibroblasts, we incubated control, 
LITAF KO and FIG4 KO fibroblasts with or without 
ML-SA1 (40  μM) for 36  h, immunolabelled LAMP1 
and cathepsin D, then analysed late endosome/lyso-
some size by confocal microscopy (Fig.  6a, Additional 
file  4: Fig.  4). The diameter of LAMP1 positive orga-
nelles was measured and the percentage of cells with 
LAMP1 organelles over 2 μm calculated (Fig. 6b). Incu-
bation of control fibroblasts with ML-SA1 did not alter 
the proportion of cells with LAMP1 organelles over 2 μm 
(mock, 8.53 ± 0.38%; + ML-SA1, 8.70 ± 0.74%). LITAF 
KO fibroblasts showed an increased proportion of cells 
with enlarged LAMP1 compartments (40.97 ± 6.14%), 
that was reduced following treatment with ML-SA1 
(14.89 ± 1.17%). Consistent with the published data on 
mouse KO fibroblasts, the majority of human FIG4 KO 
fibroblasts displayed enlarged LAMP1 positive organelles 
(97.22 ± 1.39%), but the proportion of cells with enlarged 
organelles was dramatically reduced following ML-SA1 
treatment (25.98 ± 6.76%). By EM, we observed a dra-
matic reduction in the appearance of vacuolated com-
partments in LITAF KO fibroblasts, FIG4 KO fibroblasts, 
and also CMT1C fibroblasts with the T115N LITAF 
mutation, after the incubation with ML-SA1 (Fig.  6c, 
Additional file 5: Fig. 5).
Discussion
The development of effective treatments for inherited 
neurological disorders such as CMT remains an elu-
sive goal. Despite rapid advances in the identification of 
mutations in disease-associated genes, these impressive 
discoveries have yet to be translated into proven thera-
pies. This is particularly pertinent in CMT, where dis-
ease-associated mutations in more than 100 genes have 
now been described, leading us to question whether 
treatments for CMT will be subtype specific, or if thera-
peutic targets common to more than one-subtype can be 
identified. These efforts will ultimately depend on estab-
lishing the function and pathological consequences of 
CMT-associated mutations at the subcellular and cellular 
levels.
Our observations that pathological CMT-associated 
mutations in LITAF resulted in enlargement and vacuola-
tion of late endosomal/lysosomal compartments, without 
any obvious effect on the morphology of compartments 
labelled with markers of early endosomes, are consistent 
with previous data showing that LITAF associates with 
endosomal membranes. However, the precise mechanism 
by which mutations in LITAF cause an autosomal domi-
nant disease has been the subject of debate. That is, does 
the expression of LITAF harbouring CMT1C-associated 
pathogenic mutations lead to a toxic ‘gain of function,’ 
or instead results in loss of function, either by haploin-
sufficiency or by a ‘dominant-negative’ mechanism? The 
answer to this question has crucial implications for the 
development of therapeutic strategies for this subtype of 
demyelinating CMT.
Our data argue strongly that CMT1C is the result 
of overall loss of function of LITAF in vivo, rather than 
a toxic ‘gain of function.’ This is supported by the fact 
that we observed the same enlargement and vacuola-
tion of endolysosomes in patient fibroblasts taken from 
CMT1C patients and in fibroblasts depleted of the 
LITAF protein, and consistent with the work of Zhu et al. 
who reported endolysosomal abnormalities in primary 
embryonic fibroblasts taken from mice either depleted 
of or expressing wild type and CMT1C-mutated Litaf 
protein at endogenous levels [45]. But is this loss of func-
tion due to haploinsufficiency (whereupon the expression 
of one wild-type allele is insufficient to maintain nor-
mal endolysosomes) or does LITAF protein harbouring 
CMT1C pathogenic mutations act in a ‘dominant-nega-
tive’ fashion (somehow impacting on the product of the 
wild-type allele leading to overall loss of function)? To 
address this, and arguing against haploinsufficiency, we 
can turn to the mice generated by Lee et  al. where the 
two endogenous wild type Litaf alleles could not prevent 
the development of a demyelinating peripheral neuropa-
thy in the presence of overexpressed exogenous LITAF 
harbouring the pathogenic W116G CMT1C-associated 
mutation [22]. Nevertheless, why the LITAF knock-out 
mice described by Somandin et  al. were relatively unaf-
fected is currently unclear, although the ultrastructure of 
any knock-out cells was not described in their study. This 
apparent physiological compensation could be explained 
by mechanisms such as the upregulation of other pro-
teins at an early stage, possibly including the only other 
LITAF domain-containing protein encoded in the human 
genome, CDIP1 (cell death involved p53 target 1) or 
that the progressive peripheral nerve degeneration that 
characterises CMT in humans has yet to manifest in 
18  month old mice [40]. Taken together, we therefore 
believe that our observations support a ‘dominant nega-
tive’ pathomechanisms that leads to disease in CMT1C, 
possibly mediated by the sequestering via oligomerisa-
tion of wild type LITAF by the mutant LITAF protein [14, 
21] leading to mislocalisation, aggregation and overall 
loss of function in vivo [12, 21].
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Fig. 4 Mutations in LITAF result in loss-of-function, through a dominant-negative mechanism, rather than by toxic gain-of function. LITAF knockout 
(KO) Control, L125P and T115N patient fibroblasts were generated by CRISPR/Cas9. Antibiotic selection was used to maintain Cas9 and gRNA 
transduced cells, generating mixed populations of KO cells. a Western blotting was performed to confirm the loss of LITAF protein from mixed cell 
populations. Alpha-tubulin served as loading control. Full-length blots are shown in Additional file 2: Fig. 2. b Representative confocal microscopy 
images of fixed fibroblast lines that had been stained using an anti-LITAF antibody, to show the loss of LITAF expression from ~ 95% of cells. c 
Electron micrographs of control fibroblasts expressing Cas9, and following LITAF KO, and Cas9 expressing T115N fibroblasts, and following LITAF KO. 
LITAF KO cells display swollen endocytic compartments from either control backgrounds or T115N backgrounds
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Fig. 5 FIG4 KO fibroblasts display exaggerated swollen compartments. a Control fibroblasts were depleted for FIG4 by CRISPR/Cas9 and mixed 
populations were grown. Western blotting confirms loss of FIG4 protein. b FIG4 KO fibroblasts display swollen LAMP1 positive compartments 
that can also be seen by Differential Interference Contrast (DIC). c FIG4 KO fibroblasts contain vacuolar compartments visualised by conventional 
electron microscopy. d Correlative Light and Electron Microscopy (CLEM) of FIG4 KO fibroblasts transfected with the PtdIns(3)P probe, PX-GFP. GFP 
fluorescence displays overlap with smaller endocytic organelles, but not large compartments
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Disrupted and swollen endocytic compartments have 
previously been described in a different subtype of CMT, 
CMT4J, associated with loss of function of the lipid phos-
phatase, FIG4. Given the apparent morphological simi-
larities between fibroblast taken from CMT1C patients 
and fibroblasts depleted of FIG4, we next focused on 
compartments of the late endocytic pathway. These com-
partments comprise late endosomes, endolysosomes and 
lysosomes, which are interactive, dynamic and play mul-
tiple functional roles such as macromolecule degrada-
tion, nutrient sensing, signalling to the cell nucleus, and 
plasma membrane repair [25, 36]. Late endosomes are 
multivesicular bodies formed by a maturation process 
from early endosomes [15] and deliver endocytosed 
macromolecules for degradation by lysosomal hydro-
lases through kissing and fusion with lysosomes. This 
process eventually results in the formation of endolys-
osomes, which are the principal sites of acid hydrolase 
activity and from which re-usable, terminal lysosomes 
are re-formed [4]. A key regulator of the dynamics of late 
endosomal/lysosomal compartments is the phospho-
inositide, PtdIns(3,5)P2. Reduction of PtdIns(3,5)P2 syn-
thesis by depletion or pharmacological inhibition of the 
lipid kinase PIKfyve leads to the disruption of homeosta-
sis and the resulting vacuolation of late endosomal/lyso-
somal compartments due to an imbalance of lysosome 
Fig. 6 Enlarged endocytic compartments present in LITAF KO or FIG4 KO fibroblasts can be rescued by incubation of cells with the mucolipin 
activator, ML-SA1. a Immunofluorescence of LITAF KO fibroblasts display enlarged lysosomes, shown by LAMP1 fluorescence that can be reduced 
by incubation with the TRPML1 agonist, ML-SA1 (40 μM, 36 h). b Quantification of control, LITAF KO or Fig. 4 KO fibroblasts with LAMP1 organelles 
larger than 2um, with and without incubation with ML-SA1 (40 μM, 36 h). 3 independent experiments were performed, and from each experiment 
at least 20 cells were quantified. Data shown represents mean and S.E.M. Two-tailed, unpaired T-tests were used to analyse the statistical differences 
−/+ ML-SA1. *p < 0.05, **p < 0.01, ***p < 0.001. Total number of cells analysed; L261−ML-SA1, 106; L261+ML-SA1, 102; LITAF KO−ML-SA1, 96; LITAF 
KO+ML-SA1, 98; FIG4 KO–ML-SA1, 79; FIG4 KO + ML-SA1, 83). P values (L261; 0.8519, LITAFKO; 0.04676, FIG4 KO; 0.006978). c Conventional electron 
microscopy of LITAF KO fibroblasts without and with incubation with the TRPM1 agonist, ML-SA1 (40 μM, 36 h)
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fusion with endosomes and the reformation of lysosomes 
[2, 7, 9]. Both processes are mediated by the release of 
lysosomal  Ca2+ via the TRPML1 channel, which is acti-
vated by PtdIns(3,5)P2 [8]. However, lysosome re-forma-
tion, which requires the presence of TRPML1, appears 
to be disproportionately inhibited by the absence of 
PtdIns(3,5)P2, possibly because lysosomal  Ca2+ released 
into the cytosol is required for the extension and/or exci-
sion of the membrane bridges connecting endolysosomes 
to nascent re-forming lysosomes [27]. In addition to the 
vacuolation of late endocytic compartments due to inhi-
bition of PIKfyve, mutations in FIG4 or VAC14, encod-
ing other components of the PIKfyve complex, also cause 
vacuolation of late endosomal/lysosomal compartments. 
Although FIG4 is a lipid phosphatase which can act on 
PtdIns(3,5)P2, its functional role in the PIKfyve complex 
appears to be phosphatase-independent and has been 
proposed to act alongside VAC14 in a scaffolding capac-
ity to enable PIKfyve activity [1, 6, 23]. The role of  Ca2+ 
release via TRPML1 can be seen in FIG4 KO fibroblasts 
where partial rescue of the vacuolation phenotype can be 
achieved in these cells by incubation with the small mol-
ecule synthetic activator of TRPML1, ML-SA1 ( [46] and 
see Results section). Furthermore, and consistent with 
disruption of PIKfyve activity, fibroblasts taken from a 
patient with a biallelic loss-of-function variant in VAC14 
were recently reported to contain numerous swollen 
cytoplasmic vacuoles, a phenotype that was also par-
tially rescued by ML-SA1 [24]. Although a similar rescue 
of vacuolation with ML-SA1 was not reported follow-
ing pharmacological inhibition of PIKfyve in HeLa cells 
[2], this apparently negative finding could be explained 
by the much shorter incubation time used, 2 h in HeLa 
cells compared to 24 h or longer with the FIG4 KO and 
VAC14 patient cells [24, 46]. Whether this implies an 
effect beyond simply modulating the amount of fusion 
and fission of lysosomes is unclear. Certainly, release of 
lysosomal  Ca2+ through TRPML1 can have other effects, 
not least in stimulating dephosphorylation of transcrip-
tion factor EB, resulting in its entry into the nucleus and 
upregulating genes required for lysosome biogenesis [26].
Our observation that the enlargement and vacuolation 
of late endosomal/lysosomal compartments in CMT1C 
and LITAF KO fibroblasts can also be partially reversed 
with ML-SA1 strongly suggests that LITAF functions on 
the same endolysosomal pathway as FIG4. LITAF is an 
endosomal membrane protein but whether it interacts 
with the machinery of PtdIns(3,5)P2 production or has an 
independent effect on TRPML1 is presently unknown.
CMT1C manifests clinically as a demyelinating sen-
sorimotor neuropathy where Schwann cell dysfunction 
is presumed to lead to peripheral nerve demyelination. 
Contrary to other subtypes of demyelinating CMT where 
the mutated proteins appear to play specific and special-
ised roles in Schwann cell function (e.g. SH3TC2, MPZ, 
PMP22, EGR2), LITAF is widely expressed across many 
cell types and tissues. Therefore, in contrast to other tis-
sues and cells which have capacity to functionally com-
pensate, Schwann cells might be exquisitively sensitive to 
cumulative endocytic disruption over time, leading to the 
eventual inability to maintain the highly complex state 
of myelination. This notion is supported by the num-
ber of genes found to be associated with CMT that have 
known or predicted roles in endocytic membrane traffic. 
Furthermore, while CMT1C is characterised by an iso-
lated progressive demyelinating peripheral neuropathy, 
CMT4J is recognised as a much more severe autosomal 
recessive form of the disease. It is therefore tempting to 
speculate that these differential clinical observations are 
related to the very large vaculoes (over 10 μm) found in 
FIG4 KO fibroblasts but not in fibroblasts from CMT1C 
patients or in fibroblasts depleted of wild type LITAF.
Our investigations have been conducted on fibroblasts, 
but it is the functional effects of LITAF and FIG4 muta-
tions in Schwann cells that are likely to help explain the 
underlying pathomechanism of these inherited demyeli-
nating peripheral neuropathies. This raises the question 
of which specialised pathways in Schwann cells might be 
vulnerable as a result of the enlargement and vacuola-
tion of late endosomal/lysosomal compartments. Inter-
estingly, although distinct differences exist between the 
formation and maintenance of myelin in the central and 
peripheral nervous systems, the loss of FIG4 in mouse 
oligodendrocytes (the myelin-forming glia of the central 
nervous system) leads to the accumulation of specific 
strucutral myelin proteins such as MAG (Myelin Associ-
ated Glycoprotein) within perinuclear LAMP-1 positive 
vesicles [28]. Similarly, the maintenance of peripheral 
nerve myelination and the structural integrity of spe-
cialised regions such as the nodes of Ranvier and adja-
cent paranodes rely on the trafficking and recycling of 
specialised membrane receptors in Schwann cells. For 
example, the interactions between Schwann cells and 
axons are mediated in part by various cellular adhesion 
molecules such as integrins; a family of transmembrane 
proteins that facilitate interactions between cells and the 
extracellular matrix, along with mediating specific cell–
cell interactions. Integrins are heterodimers formed by 
stable non-covalently associated α and β subunits. 18 α 
and 8 β subunits form 24 distinct integrin heterodimers, 
although integrins of the β1 family predominate in the 
peripheral nervous system and loss of integrin function 
impairs the abilty of Schwann cells to interact properly 
with axons [11, 29]. β1 integrins recycle to the plasma 
membrane from endocytic compartments, including late 
endosomes [31] and disruption to the endocytic pathway 
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reduces β1 integrin recycling to the plasma membrane 
[33]. We therefore hypothesise that endosomal dysfunc-
tion might alter the trafficking of key membrane proteins 
such as β1 integrin in a number of demyelinating CMTs 
of different subtypes (such as CMT1C and CMT4J), and 
that TRPML1 activators may be an attractive starting 
point for the development of drugs that may stabilise and 
also reverse the clinical phenotypes associated with more 
than one subtype of this currently untreatable group of 
inherited neuromuscular disorders.
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Additional file 1: Fig. 1 Comparison of markers of the endomembrane 
system between control and LITAF mutant patient fibroblasts. Control 
and LITAF mutant fibroblasts (L125P, T115N) displayed no consistent 
differences in staining for several markers of endocytic compartments, 
autophagosomes or the Golgi, as shown by confocal immunofluores-
cence microscopy using antibodies against APPL1, EEA1, CD63, LBPA, 
ubiquitin, LC3B, CIMPR and TGN46.
Additional file 2: Fig. 2  Full-length blots. Full-length blots from Figs. 1d 
and 4a. Cropped areas are highlighted and labelled.
Additional file 3: Fig. 3 Swollen compartments are accessible to 
endocytic tracers. Further examples of Fig. 2b. Control or LITAF mutant 
fibroblasts were incubated with fluid-phase HRP for 4 h before being 
fixed. A DAB reaction was performed on cells before being processed for 
conventional electron microscopy.
Additional file 4: Fig. 4  ML-SA1 rescues enlarged LAMP1 positive com-
partments from LITAF KO and FIG4 KO fibroblasts. Immunofluorescence 
showing LAMP1 and Cathepsin D labelling in control, LITAF KO and FIG4 
KO fibroblasts without and with treatment with ML-SA1 (40μM, 36 h).
Additional file 5: Fig. 5 ML-SA1 reduces the frequency of vacuolar 
endocytic compartments from T115N LITAF patient fibroblasts, and 
FIG4KO fibroblasts. Conventional electron microscopy of T115N fibroblasts 
(a) and FIG4 KO fibroblasts (b) without and with treatment with ML-SA1 
(40μM, 36 h).
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